A method for determining sensitivity to breast cancer neoadjuvant chemotherapy comprising the steps of: preparing a measurement sample comprising RNA from a.specimen collected from a subject, measuring an expression level of each gene of to below making use of a measurement sample obtained in step, analyzing an expression level of each gene measured in step, and determining sensitivity to breast cancer neoadjuvant chemotherapy on the basis of an analysis result obtained in step, wherein is human caspase recruitment domain family, member 9 (CARD9) gene, is human indoleamine-2,3-dioxygenase 1 gene, is human chemokine (C-X-C motif) ligand 9 (CXCL9) gene, is human purine nucleoside phosphorylase gene, is human chemokine (C-X-C motif) ligand 11 (CXCL11) gene, is human CCAAT/enhancer binding protein (CEBPB) gene, is human CD83 gene, is human interleukin 6 signal transducer (IL6ST) gene, is human chemokine (C-X3-C) receptor 1 (CX3CR1) gene, is human CD1D gene, is human cathepsin C (CTSC) gene, is human chemokine (C-X-C motif) ligand 10 (CXCL10) gene, is human immunoglobulin heavy chain genetic locus G1 isotype (IGHG1) gene, is human zinc finger E-box-binding homeobox 1 gene, is human vascular endothelial growth factor A (VEGFA) gene, is human semaphorin-3C precursor (SEMA3C) gene, is human complement receptor gene, is human HFE gene, and is human EDA gene. preparing a measurement sample comprising RNA from a.specimen collected from a subject, measuring an expression level of each gene of to below making use of a measurement sample obtained in step, analyzing an expression level of each gene measured in step, and determining sensitivity to breast cancer neoadjuvant chemotherapy on the basis of an analysis result obtained in step, wherein is human caspase recruitment domain family, member 9 (CARD9) gene, is human indoleamine-2,3-dioxygenase 1 gene, is human chemokine (C-X-C motif) ligand 9 (CXCL9) gene, is human purine nucleoside phosphorylase gene, is human chemokine (C-X-C motif) ligand 11 (CXCL11) gene, is human CCAAT/enhancer binding protein (CEBPB) gene, is human CD83 gene, is human interleukin 6 signal transducer (IL6ST) gene, is human chemokine (C-X3-C) receptor 1 (CX3CR1) gene, is human CD1D gene, is human cathepsin C (CTSC) gene, is human chemokine (C-X-C motif) ligand 10 (CXCL10) gene, is human immunoglobulin heavy chain genetic locus G1 isotype (IGHG1) gene, is human zinc finger E-box-binding homeobox 1 gene, is human vascular endothelial growth factor A (VEGFA) gene, is human semaphorin-3C precursor (SEMA3C) gene, is human complement receptor gene, is human HFE gene, and is human EDA gene. is human caspase recruitment domain family, member 9 (CARD9) gene, is human indoleamine-2,3-dioxygenase 1 gene, is human chemokine (C-X-C motif) ligand 9 (CXCL9) gene, is human purine nucleoside phosphorylase gene, is human chemokine (C-X-C motif) ligand 11 (CXCL11) gene, is human CCAAT/enhancer binding protein (CEBPB) gene, is human CD83 gene, is human interleukin 6 signal transducer (IL6ST) gene, is human chemokine (C-X3-C) receptor 1 (CX3CR1) gene, is human CD1D gene, is human cathepsin C (CTSC) gene, is human chemokine (C-X-C motif) ligand 10 (CXCL10) gene, is human immunoglobulin heavy chain genetic locus G1 isotype (IGHG1) gene, is human zinc finger E-box-binding homeobox 1 gene, is human vascular endothelial growth factor A (VEGFA) gene, is human semaphorin-3C precursor (SEMA3C) gene, is human complement receptor gene, is human HFE gene, and is human EDA gene.